RxDoctor Payments Data

Erin Gerken

Nurse Practitioner · Rossford, OHNPI 1669062964

Payments from drug & device makers

$6,963in general payments, 2019–2025

Across 204 payments — averaging $34.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$574
  • Bayer$492
  • Teva Pharmaceuticals USA, Inc.$490
  • Novo Nordisk$374
  • GSK$314
  • plus $3K from 36 others

What the payments were for

  • Speaking & faculty fees$521%
  • Food & beverage$6,91199%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,963 in reported general payments places this provider in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

See all nurse practitioner providers in Ohio

Medicare billing

Part B allowed, 2024
$60,844
Medicare patients
187
Services billed
762

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine11$115,969
EliquisApixaban125$51,429
JardianceEmpagliflozin65$31,383
TrulicityDulaglutide31$23,414
EntrestoSacubitril/Valsartan23$13,401
MyrbetriqMirabegron19$8,855
XareltoRivaroxaban17$5,076
LokelmaSodium Zirconium Cyclosilicate22$5,014
Breo ElliptaFluticasone/Vilanterol20$4,982
JanuviaSitagliptin Phosphate12$4,315
GemtesaVibegron15$4,263
Incruse ElliptaUmeclidinium Bromide12$3,145
Sertraline Hcl110$3,109
Sucralfate27$2,938
Meropenem19$2,381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$490$115,96911 claims
PfizerEliquis$62$51,429125 claims
Boehringer IngelheimJardiance$147$31,38365 claims
Lilly USA, LLCTrulicity, Olanzapine$260$24,29578 claims
NovartisEntresto$66$13,40123 claims
GSKBreo Ellipta, Incruse Ellipta$314$8,12732 claims
Johnson & JohnsonXarelto$192$5,07617 claims
AstraZenecaLokelma$574$5,01422 claims
Sumitomo Pharma America, Inc.Gemtesa$259$4,26315 claims
Sanofi-aventis U.S. LLCLantus$30$1,21915 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$52$1,10913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,700 nurse practitioner providers in Ohio.

Other nurse practitioner in Rossford

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →